This was the stock's third consecutive day of losses.
Edwards Lifesciences Corp. closed 23.74% short of its 52-week high of $96.12, which the company achieved on March 28th.
Zovighian said the transition to CEO has been relatively smooth since he joined Edwards in 2015 and spent eight years in ...
Edwards Lifesciences’ EW fourth-quarter performance was backed by its most comprehensive structural heart disease portfolio. The Surgical Structural Heart business is benefiting from the strong ...
Edwards Lifesciences had a net margin of 72.93% and a return on equity of 19.40%. Equities research analysts anticipate that Edwards Lifesciences Co. will post 2.45 EPS for the current fiscal year ...
Edwards Lifesciences Corp. engages in the patient-focused medical innovations for heart disease and critical care monitoring. Its products are categorized into three areas: Transcatheter Heart ...
We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...
5d
Hosted on MSNShould Edwards Lifesciences Stock Remain in Your Portfolio Now?Edwards Lifesciences’ EW fourth-quarter performance was backed by its most comprehensive structural heart disease portfolio. The Surgical Structural Heart business is benefiting from the strong ...
A federal court granted summary judgment to Edwards Lifesciences LLC on a Title VII failure to accommodate religious observance claim of a senior cardiovascular specialist who alleged that Edwards ...
6h
24/7 Wall St. on MSNWorld’s Third-Largest Pension Fund Poured Half a Billion Into These 2 StocksSouth Korea’s National Pension Fund (NPF) is the world’s third-largest pension fund by total assets. It manages 1,185.2 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results